These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 11108907)

  • 1. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
    Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
    Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
    Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
    Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
    Bachand B; Tarazi M; St-Denis Y; Edmunds JJ; Winocour PD; Leblond L; Siddiqui MA
    Bioorg Med Chem Lett; 2001 Feb; 11(3):287-90. PubMed ID: 11212093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
    Qiu X; Wang W; Zhao Z; Sun S; Tang L
    Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
    Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
    Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
    Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U
    Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
    Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
    Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
    Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
    Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
    Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
    Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ
    J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
    Chi L; Pen YW; Potoczak R; Gibson G; Hicks G; Mertz TE; Janiczek N; Juneau PL; Gallagher K; Leadley R
    Pharmacology; 2002 Feb; 64(2):76-83. PubMed ID: 11803247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.